CAPriCORN's Response to COVID-19
Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) is a study that compared the effectiveness of two daily doses of aspirin widely used to prevent heart attacks and strokes in individuals living with heart disease.
Funded through a Patient-Centered Outcomes Research Institute (PCORI) Award, ADAPTABLE spanned the U.S. and was the first demonstration project conducted through PCORnet, the National Patient-Centered Clinical Research Network. PCORnet is a PCORI-funded initiative designed to improve the nation’s capacity to conduct comparative clinical effectiveness research.
CAPriCORN worked with partners in Chicagoland to recruit patients during office visits and in non-clinical settings in underserved communities.
The ADAPTABLE study closed enrollment on July 1, 2019, with more than 15,000 participants. We are currently working on follow-ups for this study.
References in this website to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the members of the Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN).